A Confluent, Crusty Rash

Zasocitinib showed significant efficacy in treating moderate-to-severe plaque psoriasis, outperforming placebo and apremilast in pivotal phase 3 trials.

Linda Stein Gold, MD, reviews AAD’s 2025 updates on new topical and biologic options for adult atopic dermatitis.

Phase 2b REZOLVE-AA trial results show rezpegaldesleukin reduced SALT scores versus placebo in severe alopecia areata, supporting Phase 3 development.

Insights on atopic dermatitis treatment preferences, the safety of childhood vaccines, maternal depression’s effect on parenting, and more.

Findings support the importance of integrating behavioral health assessment into dermatology visits, particularly for patients with high quality-of-life impairment.

A practical, evidence-based overview of how to recognize hidradenitis suppurativa early, stage disease severity, and coordinate care before progression.